Literature DB >> 24406386

Subfoveal choroidal thickness in retinal angiomatous proliferation.

Taizo Yamazaki1, Hideki Koizumi, Tetsuya Yamagishi, Shigeru Kinoshita.   

Abstract

PURPOSE: To investigate the subfoveal choroidal thickness in patients with retinal angiomatous proliferation (RAP).
METHODS: In consecutive patients with RAP, subfoveal choroidal thickness was retrospectively measured by the use of enhanced depth imaging spectral domain optical coherence tomography in comparison with age-matched control subjects.
RESULTS: Nineteen eyes of 19 patients with RAP and 32 eyes of 32 control subjects were included in this study. No significant differences were found between the eyes with RAP and the control eyes regarding age, gender, spherical equivalent, and axial length. Mean subfoveal choroidal thickness in 19 eyes with RAP was significantly less than that in the control eyes (129.5 ± 35.8 μm vs. 201.3 ± 55.0 μm, P < 0.0001). The difference in mean subfoveal choroidal thickness between eyes with Stage 2 RAP (132.8 ± 38.2 μm) and eyes with Stage 3 RAP (126.4 ± 36.6 μm) was not significant, though each measurement was significantly less than that in the control eyes (P < 0.001 and P = 0.002, respectively).
CONCLUSION: Eyes with RAP had a significantly thinner subfoveal choroid compared with normal eyes. Such morphologic features may be related to the pathologic mechanism of RAP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24406386     DOI: 10.1097/IAE.0000000000000086

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  Quantitative assessment of choriocapillaris flow deficits in eyes with macular neovascularization.

Authors:  Federico Corvi; Mariano Cozzi; Giulia Corradetti; Giovanni Staurenghi; David Sarraf; SriniVas R Sadda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-08       Impact factor: 3.117

2.  Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.

Authors:  Tamaki Tamashiro; Koji Tanaka; Kanako Itagaki; Makiko Nakayama; Ichiro Maruko; Sorako Wakugawa; Nobuhiro Terao; Hajime Onoe; Yu Wakatsuki; Masashi Ogasawara; Yukinori Sugano; Akiko Yamamoto; Keiko Kataoka; Takahiko Izumi; Moeko Kawai; Ryusaburo Mori; Tetsuju Sekiryu; Annabelle A Okada; Tomohiro Iida; Hideki Koizumi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-16       Impact factor: 3.117

Review 3.  Choroidal imaging using optical coherence tomography: techniques and interpretations.

Authors:  Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2022-02-16       Impact factor: 2.447

4.  Distinguishing retinal angiomatous proliferation from polypoidal choroidal vasculopathy with a deep neural network based on optical coherence tomography.

Authors:  Daniel Duck-Jin Hwang; Seong Choi; Junseo Ko; Jeewoo Yoon; Ji In Park; Joon Seo Hwang; Jeong Mo Han; Hak Jun Lee; Joonhong Sohn; Kyu Hyung Park; Jinyoung Han
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

5.  Classifying neovascular age-related macular degeneration with a deep convolutional neural network based on optical coherence tomography images.

Authors:  Jinyoung Han; Seong Choi; Ji In Park; Joon Seo Hwang; Jeong Mo Han; Hak Jun Lee; Junseo Ko; Jeewoo Yoon; Daniel Duck-Jin Hwang
Journal:  Sci Rep       Date:  2022-02-09       Impact factor: 4.379

Review 6.  Choroidal Vasculature Changes in Age-Related Macular Degeneration: From a Molecular to a Clinical Perspective.

Authors:  Serena Fragiotta; Luca Scuderi; Clemente Maria Iodice; Daria Rullo; Mariachiara Di Pippo; Elisa Maugliani; Solmaz Abdolrahimzadeh
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

7.  Unaffected fellow eye neovascularization in patients with type 3 neovascularization: Incidence and risk factors.

Authors:  Jae Hyuck Kwak; Woo Kyung Park; Rae Young Kim; Mirinae Kim; Young-Gun Park; Young-Hoon Park
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.